2024
Clinical characteristics associated with problematic pornography use among individuals seeking treatment for opioid use disorder.
Stefanovics E, Kraus S, Madden L, Farnum S, Cannata E, Potenza M, Barry D. Clinical characteristics associated with problematic pornography use among individuals seeking treatment for opioid use disorder. Journal Of Behavioral Addictions 2024 PMID: 39298267, DOI: 10.1556/2006.2024.00037.Peer-Reviewed Original ResearchBrief Pornography ScreenOpioid use disorderPornography useOpioid use disorder treatmentUse disorderMeasures of substance useMeasures of impulsivityProblematic pornography useMinority of individualsNegative urgencyPositive urgencyPsychotic symptomsSelf-reported dataBehavioral addictionsGambling disorderPsychiatric disordersPsychiatric symptomsSensation-seekingEmotional labilitySelf-harmSubstance useDisordersOpioidIndividualsSymptomsThe cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retentionPerceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment
Gazzola M, Oberleitner L, Hoffman K, Eller A, Madden L, Marcus R, Oberleitner D, Beitel M, Thompson E, Zheng X, Barry D. Perceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment. Substance Use & Addiction Journal 2024, 45: 568-576. PMID: 38551080, DOI: 10.1177/29767342241238837.Peer-Reviewed Original ResearchCommunity corrections officersCommunity corrections systemCorrection systemCommunity correctionsTreatment facilitatorsOpioid use disorderCorrective experiencesMethadone treatmentSubstance use disorder careCommunity supervisionCorrectional officersQualitative studyCoercive treatmentIncarceration historyOutpatient methadone treatmentIncarcerationDemographic surveyQualitative research teamNegative experiencesNegative perceptionsCommunitySemistructured interviewsPositive perceptionsInterviewsParoleA Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment
Gazzola M, Carmichael I, Thompson E, Beitel M, Madden L, Saeed G, Hoffman K, Hammouri M, Hsaio C, Barry D. A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment. Journal Of Addiction Medicine 2024, 18: 262-268. PMID: 38446859, DOI: 10.1097/adm.0000000000001282.Peer-Reviewed Original ResearchBrain disease modelMethadone treatmentTreatment beliefsIllness modelAssociated with beliefsOpioid use disorderUse disorderOutpatient opioid treatment programAddiction modelTreatment programsOpioid treatment programsAddictionMethadoneMultivariate analysisScale agreementIllnessDisordersCounselingBrainBeliefsDisease modelsOpioidPatientsStatistical significanceMultivariate regressionPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisordersPreferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger studyLeveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees
Nikitin B, Bromberg D, Madden L, Stöver H, Teltzrow R, Altice F. Leveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees. PLOS Global Public Health 2023, 3: e0002168. PMID: 37440470, PMCID: PMC10343058, DOI: 10.1371/journal.pgph.0002168.Peer-Reviewed Original ResearchOpioid use disorderAgonist maintenance therapyMaintenance therapyInjection drug usePrevention of HIVGold standard treatmentRisk of HIVHigh prevalence ratesCare continuityStandard treatmentPrevalence ratesUse disordersImplementation science lensDrug useHarm reductionTreatment modelHIVPatientsClinicTherapyAddiction treatment modelsTreatmentProvidersInvasionInterview participantsCorrelates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment
Nwanaji-Enwerem U, Beitel M, Oberleitner D, Gazzola M, Eggert K, Oberleitner L, Jegede O, Zheng X, Redeker N, Madden L, Barry D. Correlates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment. Journal Of Psychoactive Drugs 2023, 56: 530-540. PMID: 37399330, PMCID: PMC10761588, DOI: 10.1080/02791072.2023.2230571.Peer-Reviewed Original ResearchMethadone maintenance treatmentSubstance use disordersLogistic regression modelsUse disordersMaintenance treatmentTreatment-related characteristicsOpioid use disorderFinal logistic regression modelBSI-18 depressionAge of onsetRegression modelsMMT programDepressive symptomsMeasures of demographicsPatientsBivariate analysisSubstance abuseSignificant correlatesDisordersCorrelatesMedian splitAgeParticipantsTreatmentLikert-type scaleApplication of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions“Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories
Hoffman K, Thompson E, Gaeta Gazzola M, Oberleitner L, Eller A, Madden L, Marcus R, Oberleitner D, Beitel M, Barry D. “Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories. Addiction Science & Clinical Practice 2023, 18: 16. PMID: 36944998, PMCID: PMC10031976, DOI: 10.1186/s13722-023-00377-y.Peer-Reviewed Original ResearchConceptsOpioid use disorderRe-entry experiencesReintegration of peopleSemi-structured qualitative interviewsIncarceration historyExperiences of peoplePerspectives of peopleBasic resourcesThematic analysis approachTransition programCarceral settingsQualitative interviewsLived experienceStable housingStructural barriersSocial challengesFormal transition programQualitative investigationPersistent barriersIncarcerationHistory of incarcerationUse disordersConcrete suggestionsMain themesRe-entry periodA National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States
Gazzola M, Carmichael I, Christian N, Zheng X, Madden L, Barry D. A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States. Substance Abuse 2023, 44: 62-72. PMID: 37226909, DOI: 10.1177/08897077231167291.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersClinical characteristicsTreatment completionTreatment engagementTreatment Episodes Dataset-DischargesSocial determinantsLogistic regression modelsImportant social determinantOutpatient medicationsTreatment discontinuationIndependent predictorsCare treatmentTreatment episodesTreatment enrollmentMedical conditionsSDoH variablesHealth outcomesTreatment lengthGreater social vulnerabilityTreatment entryMOUDVulnerable populationsPoor engagementMedications
2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersEnhancing Use of Medications for Opioid Use Disorder Through External Coaching
Molfenter T, Kim H, Kim JS, Kisicki A, Knudsen HK, Horst J, Brown R, Madden LM, Toy A, Haram E, Jacobson N. Enhancing Use of Medications for Opioid Use Disorder Through External Coaching. Psychiatric Services 2022, 74: 265-271. PMID: 36196533, PMCID: PMC10836327, DOI: 10.1176/appi.ps.202100675.Peer-Reviewed Original ResearchConceptsOpioid use disorderBuprenorphine useControl armUse disordersUse of MOUDUse of medicationsInjectable naltrexoneNaltrexone administrationOutcome measuresCoaching armClinical sitesHealth systemProvider UtilizationTrial periodTreatment agenciesTrialsDelivery modalitiesHealth sitesMedicationsSignificant differencesDisordersArmSimilar patternMOUDNaltrexoneWhat’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment
Gazzola MG, Maclean E, Beitel M, Carmichael ID, Cammack KM, Eggert KF, Roehrich T, Madden LM, Jegede O, Zheng X, Bergman E, Barry DT. What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment. Journal Of General Internal Medicine 2022, 38: 653-660. PMID: 36163526, PMCID: PMC9971370, DOI: 10.1007/s11606-022-07813-w.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance use disordersMethadone treatmentUse disordersOutpatient methadone treatment programMethadone treatment programsPresenting problemPreferences of patientsTerminology preferencesSubstance-dependent personsCross-sectional surveyAdult patientsMean ageUnivariate analysisMain MeasuresParticipantsPatientsTreatment programKey ResultsWeSubstance abuseSubstance useDisordersSignificant differencesTreatmentDemographic differencesAddiction counselorsStrengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirusPregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health.
Madden L, Oliva J, Eller A, DiDomizio E, Roosa M, Blanchard L, Kil N, Altice F, Johnson K. Pregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health. American Journal Of Law & Medicine 2022, 48: 209-222. PMID: 36715261, DOI: 10.1017/amj.2022.26.Peer-Reviewed Original ResearchConceptsOpioid use disorderReproductive healthPregnant womenUse disordersPregnant women's useEvidence-based treatmentsReproductive health outcomesWomen's reproductive healthIntersection of HIVSystems of careHealth care choicesPostpartum womenChild healthTreatment policyUnintentional pregnancyHealth outcomesLarger studyWomenTransactional sexCare choicesMinority womenOutcomesOUDWomen's useDisordersCharacterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake
Oles W, Alexander M, Kumar N, Howell B, O’Connor P, Madden LM, Barry DT. Characterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake. BMC Psychiatry 2022, 22: 236. PMID: 35366844, PMCID: PMC8976510, DOI: 10.1186/s12888-022-03884-5.Peer-Reviewed Original ResearchConceptsLow-threshold clinicDemographic characteristicsOpioid use disorder treatmentMultivariate logistic regression modelBrief Pain InventoryPatient demographic characteristicsOpioid use disorderSocial supportSymptom Identification ScaleUse disorder treatmentNon-Hispanic whitesLogistic regression modelsOlder patientsPain InventoryTreatment cohortsSelf-reported social supportLife Events ChecklistMOUD treatmentBaseline disparitiesTreatment accessTreatment needsHigh riskUse disordersMortality rateDisorder treatmentThe development and initial validation of the Russian version of the BASIS-24
Madden L, Farnum S, Bromberg D, Barry D, Mazhnaya A, Fomenko T, Meteliuk A, Marcus R, Rozanova J, Poklad I, Dvoriak S, Altice F. The development and initial validation of the Russian version of the BASIS-24. Addiction Science & Clinical Practice 2022, 17: 65. PMID: 36435811, PMCID: PMC9701377, DOI: 10.1186/s13722-022-00343-0.Peer-Reviewed Original ResearchConceptsBASIS-24Addiction treatmentHIV prevention goalsSubset of patientsOpioid use disorderSymptom Identification ScaleMental health statusResultsCronbach’s alpha coefficientsMOUD patientsSeverity InstrumentTuberculosis epidemicEffective treatmentUse disordersHealth statusHealthcare professionalsMental healthPrevention goalsRelationships subscaleTreatment deliveryExploratory principal component analysisOpioidsHIVPatientsAlpha coefficientEECA region
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screening